Serum thymidine kinase (TK) evaluation in HIV infection.
Serum thymidine kinase (TK), measured using Prolifigen TK-REA, from AB Sangtec Medical, was investigated in 24 HIV seropositive patients without immunological alterations, 26 seropositives with immunological alterations, 125 LAS, 25 ARC, and 20 AIDS. Subjects with serological markers of prior EBV, HBV, and CMV infection were included but none with acute infectious mononucleosis or acute viral hepatitis. Serum TK was elevated from the beginning of the HIV infection, the seropositive stage, and more markedly afterwards during the course of the infection, with a close correlation with the stage. TK also increased during AZT treatment, due to bone-marrow toxicity. On lowering the dosage or discontinuing the drug TK returned to basal levels. Although the rise in serum may well not be correlated only with the HIV infection, it does add to the picture given by other clinical and/or laboratory methods. Serum TK can be a helpful laboratory test in the follow-up of patients with HIV infection, especially when serum levels are disproportionate to the stage, opportunistic infections, lymphoproliferative malignancies. In such cases bone-marrow toxicity due to treatment can be suspected.
Sabbatani
S
S
Infectious Diseases Department, Ospedale Maggiore, Bologna, Italy.
Fini
A
A
Raise
E
E
Gritti
F M
FM
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000201:enzymology*; D000328:Adult; D005260:Female; D006679:HIV Seropositivity / Q000201:enzymology; D006801:Humans; D008297:Male; D000091402:Prohibitins; D011869:Radioligand Assay; D013937:Thymidine Kinase / Q000097:blood*; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
C000717331:PHB2 protein, human; D000091402:Prohibitins; D015215:Zidovudine; D013937:Thymidine Kinase